# A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder

> **NCT01340027** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 1307 (actual)

## Conditions studied

- Urologic Diseases
- Urinary Bladder Diseases
- Urological Manifestations
- Signs and Symptoms
- Urinary Bladder, Overactive

## Interventions

- **DRUG:** Mirabegron
- **DRUG:** Solifenacin succinate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01340027
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-29
- **Primary completion:** 2012-06-28
- **Final completion:** 2012-06-28
- **Target enrollment:** 1307 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01340027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01340027, "A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01340027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*